Workflow
君实生物(688180) - 2022 Q3 - 季度财报
2022-10-30 16:00

Financial Performance - The company's revenue for Q3 2022 was approximately RMB 272.33 million, a decrease of 54.91% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of RMB 682.32 million for the quarter, with a cumulative loss of RMB 1.59 billion year-to-date[4] - The basic earnings per share for Q3 2022 was -0.75 yuan, with a year-to-date figure of -1.75 yuan[4] - Revenue for the first three quarters of 2022 was RMB 1,218,381,861.73, down from RMB 2,718,396,641.58 in the same period of 2021, indicating a decrease of approximately 55.2%[15] - The company reported a net loss of RMB 5,983,314,584.38 for the first three quarters of 2022, compared to a loss of RMB 4,388,585,020.16 in the same period of 2021[15] - The net profit for Q3 2022 was -1,734,538,953.68 CNY, compared to -392,126,886.59 CNY in Q3 2021, indicating a significant increase in losses[18] - The total comprehensive income for Q3 2022 was -1,755,730,362.15 CNY, compared to -368,440,990.46 CNY in Q3 2021, reflecting a worsening financial position[18] - The company reported a total operating profit of -1,716,008,666.56 CNY in Q3 2022, compared to -288,543,144.54 CNY in Q3 2021, indicating a decline in operational performance[17] Research and Development - R&D investment totaled RMB 573.88 million in Q3 2022, representing 210.73% of the revenue, an increase of 132.03 percentage points year-on-year[5] - Research and development expenses rose to 1,636,118,643.63 CNY in Q3 2022, up from 1,422,572,326.73 CNY in the same period last year[17] Assets and Liabilities - The total assets at the end of the reporting period were RMB 9.58 billion, down 13.18% from the end of the previous year[5] - As of September 30, 2022, total assets amounted to RMB 9,581,031,208.80, a decrease from RMB 11,034,911,100.95 at the end of 2021[14] - Total current assets decreased to RMB 4,261,782,626.15 from RMB 5,844,891,453.12 year-over-year[14] - Cash and cash equivalents were RMB 3,064,825,595.33, down from RMB 3,506,637,890.39 at the end of 2021, representing a decline of approximately 12.6%[14] - Accounts receivable decreased significantly to RMB 289,586,600.85 from RMB 1,293,122,136.21, a drop of about 77.6%[14] - Inventory increased to RMB 537,280,841.89 from RMB 484,601,367.48, reflecting a growth of approximately 10.9%[14] - Total liabilities were RMB 2,676,684,562.28, compared to RMB 2,718,536,814.27 in the previous year[15] - The company's equity attributable to shareholders decreased to RMB 6,555,742,303.66 from RMB 7,945,095,398.41, a decline of about 17.5%[15] Cash Flow - The company reported a net cash flow from operating activities of -1.12 billion yuan year-to-date, indicating a decline in cash inflow compared to the previous year[4] - Operating cash flow for Q3 2022 showed a net outflow of -1,117,489,221.19 CNY, compared to -540,121,393.81 CNY in Q3 2021, indicating increased cash burn[19] - The company reported cash and cash equivalents of 3,001,414,742.11 CNY at the end of Q3 2022, down from 3,147,459,500.68 CNY at the end of Q3 2021[20] Sales Performance - The sales revenue from the product Tuoyi® (JS001) reached approximately RMB 218 million in Q3 2022, marking a continuous quarter-on-quarter growth[6] - The company has received approval for six indications for Tuoyi® in China, indicating significant growth potential in the domestic market[6] - Sales revenue from goods and services received in Q3 2022 was 2,109,423,813.08 CNY, a decrease from 2,584,764,961.17 CNY in Q3 2021[19] Shareholder Information - The total number of shareholders as of the report date was 35,996, with 35,988 being A-share holders and 8 being H-share holders[14] Financial Expenses - The company incurred financial expenses of -71,341,733.51 CNY in Q3 2022, a decrease from 5,094,540.11 CNY in Q3 2021[17] - The company raised 396,975,840.00 CNY from investments in Q3 2022, significantly lower than 2,121,734,262.98 CNY in Q3 2021[20]